Om

Arch Biopartners Inc. is a Canadian therapeutic biotechnology company focused on developing novel drug candidates to prevent and treat kidney-related injury and disease. Headquartered in Toronto, it concentrates on both acute kidney injury and chronic kidney disease, conditions that represent a significant burden in critical care and chronic medicine. The company’s pipeline includes LSALT peptide, designed to address inflammation-related acute kidney injury in high-risk settings such as major surgery, and cilastatin, aimed at reducing toxin-induced kidney damage. Arch Biopartners also advances AB569, targeting antibiotic-resistant bacterial infections and difficult-to-heal wounds, and the Borg platform, which uses proprietary peptides on metal and plastic surfaces to inhibit biofilm formation and reduce corrosion. Through these programs, Arch Biopartners occupies a specialized niche at the intersection of nephrology, critical care, and anti-infective therapies within the global biopharmaceutical market.

Markedsdata leveret af TwelveData og Morningstar

Aktiemarkedet kan gå både op og ned. Selvom investeringer i aktier historisk set har givet investorer et positivt afkast på langt sigt, er der ingen garanti for fremtidige afkast. Der er derfor en risiko for, at du ikke får de investerede penge tilbage.

INVESTER I ARCH BIOPARTNERS MED ENDAVU: Køb Arch Biopartners ($8HA) aktier gennem Endavu’s investeringsplatform. Hos Endavu kan du købe og sælge aktier i Arch Biopartners, og handle med aktier, fraktionaler, ETF'er og andre finansielle instrumenter. Endavu tilbyder handel uden kurtage på amerikanske aktier. Endavu tilbyder lav kurtage på tværs af aktier. Handl med over 30.000 forskellige aktier og udenfor markedsåbningstider.